Cargando…

Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer

Immune-related adverse events, including autoimmune toxicity, may develop as a consequence of immune-checkpoint inhibitor (ICI) cancer therapy. Cytokine release syndrome (CRS) is a severe and life-threatening cytokine-associated toxicity that can develop after adoptive T-cell therapy. We herein repo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yomota, Makiko, Mirokuji, Kie, Sakaguchi, Masahiro, Kitahara, Yasuyuki, Chin, Fangyi, Setoguchi, Keigo, Hosomi, Yukio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627810/ https://www.ncbi.nlm.nih.gov/pubmed/33775995 http://dx.doi.org/10.2169/internalmedicine.5922-20

Ejemplares similares

A case of diffuse pulmonary ossification
por: Yomota, Makiko, et al.
Publicado: (2021)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
por: Fukuda, Akito, et al.
Publicado: (2022)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
por: Uehara, Yuji, et al.
Publicado: (2022)

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy
por: Uehara, Yuji, et al.
Publicado: (2022)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer
por: Kato, Yasuhiro, et al.
Publicado: (2019)

Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study
por: Takagi, Yusuke, et al.
Publicado: (2013)

Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1
por: Nakahara, Yoshiro, et al.
Publicado: (2016)

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
por: Kitagawa, Shingo, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database
por: Ceschi, Alessandro, et al.
Publicado: (2020)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome
por: Urasaki, Tetsuya, et al.
Publicado: (2021)

Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis
por: Ebata, Takahiro, et al.
Publicado: (2015)

A case of cytokine release syndrome accompanied with COVID‐19 infection during treatment with immune checkpoint inhibitors for non‐small cell lung cancer
por: Murata, Daiki, et al.
Publicado: (2022)

A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors
por: Ohira, Junichiro, et al.
Publicado: (2020)

Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature
por: Tay, Sen Hee, et al.
Publicado: (2022)

Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review
por: Hakozaki, Taiki, et al.
Publicado: (2019)

Hyper‐progressive disease after immune checkpoint inhibitor in SMARCA4‐deficient small‐cell lung carcinoma
por: Chiba, Yosuke, et al.
Publicado: (2020)

Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426
por: Ichikawa, Yasuko, et al.
Publicado: (2023)

The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy
por: Tsuruda, Toshihiro, et al.
Publicado: (2020)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors
por: Farooqui, Naba, et al.
Publicado: (2022)

Association between inflammatory cytokines and immune–checkpoint molecule in rheumatoid arthritis
por: Matsumoto, Haruki, et al.
Publicado: (2021)

Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014
por: Takagi, Yusuke, et al.
Publicado: (2015)

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
por: Kuo, Chih‐Hsi Scott, et al.
Publicado: (2019)

Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response
por: Kondratova, Maria, et al.
Publicado: (2020)

Bell's palsy during rechallenge of immune checkpoint inhibitor
por: Takemura, Kohji, et al.
Publicado: (2023)

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
por: Kleponis, Jennifer, et al.
Publicado: (2015)

Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor
por: Pradhan, Anjan K., et al.
Publicado: (2022)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor
por: Harada, Mirii, et al.
Publicado: (2023)

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma
por: Tamai, Yasuyuki, et al.
Publicado: (2023)

Effect of small heat release and viscosity on thermal-diffusive instability
por: Wada, Keigo
Publicado: (2021)

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer
por: Bridge, Jennifer A., et al.
Publicado: (2018)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors
por: Vaseq, Rohulla, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jk4kajg2n920lck41b0gfb67so